About Heparan sulfate glucosamine 3-O-sulfotransferase 1
Heparan sulfate glucosamine 3-O-sulfotransferase 1 (HS3ST1) is a protein
from Homo sapiens identified by UniProt accession
O14792, 307 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Heparan sulfate glucosamine 3-O-sulfotransferase 1 |
|---|
| UniProt accession | O14792 |
|---|
| Gene | HS3ST1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 307 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (63)
Diseases linked to this target (Open Targets).
- alcohol abuse · score 0.27
- Alzheimer disease · score 0.24
- intraocular pressure measurement · score 0.23
- neuritic plaque measurement · score 0.22
- neurodegenerative disease · score 0.22
- anxiety disorder · score 0.20
- arteriosclerosis disorder · score 0.19
- coronary artery disease · score 0.19
- arteriosclerosis · score 0.19
- urate measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14792-F1 | alphafold | PREDICTED | 90.00 | — |
Amino-acid sequence (307 residues)
MAALLLGAVL LVAQPQLVPS RPAELGQQEL LRKAGTLQDD VRDGVAPNGS AQQLPQTIII GVRKGGTRAL LEMLSLHPDV AAAENEVHFF DWEEHYSHGL GWYLSQMPFS WPHQLTVEKT PAYFTSPKVP ERVYSMNPSI RLLLILRDPS ERVLSDYTQV FYNHMQKHKP YPSIEEFLVR DGRLNVDYKA LNRSLYHVHM QNWLRFFPLR HIHIVDGDRL IRDPFPEIQK VERFLKLSPQ INASNFYFNK TKGFYCLRDS GRDRCLHESK GRAHPQVDPK LLNKLHEYFH EPNKKFFELV GRTFDWH
Explore Heparan sulfate glucosamine 3-O-sulfotransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets